India Caps Profit Margins on 137 Cancer Drugs to Curb 'Extortionate' Hospital Markups

India's government has capped trade margins on 137 critical cancer medications at 30 percent, a move expected to slash maximum retail prices by up to 70 percent starting November 9, 2026. The intervention targets the massive markups added by distributors and hospitals.[1]

The National Pharmaceutical Pricing Authority issued the directive following intense scrutiny from the Supreme Court. During recent hearings, justices highlighted disparities where a drug procured for 2,700 rupees was sold to patients for 27,000 rupees, condemning the practice as "extortion" and "broad daylight dacoity."[1][2]

For millions of patients navigating oncology care in India, the financial relief is substantial. The government estimates the margin cap will save families approximately 25 billion rupees annually. This reduction directly addresses the catastrophic out-of-pocket expenses that often accompany a cancer diagnosis.[1]

The policy shift stems from a 2022 petition filed by Sarojam Radhakrishnan, a retired bank employee from Kerala. Diagnosed with breast cancer, she sued to force government intervention after struggling to afford monthly treatment costs that exceeded 63,000 rupees.[1]

Though Radhakrishnan died in late 2022, her legal challenge reached the nation's highest court. The resulting scrutiny forced regulators to examine the unregulated segments of the pharmaceutical supply chain, revealing average trade markups of 170 percent, with some reaching 700 percent.[1][3]

How the margin cap works

The new regulation does not directly dictate the launch price that pharmaceutical manufacturers can charge for their drugs. Instead, it strictly limits the profit margin that the supply chain—distributors, stockists, and hospitals—can add before the medication reaches the patient.[3][5]

Under the directive, the trade margin is capped at 30 percent of the maximum retail price, excluding goods and services tax. This translates to a maximum allowable markup of roughly 42.8 percent on the price at which the manufacturer sells the drug to the first distributor.[6]

The 137 non-scheduled formulations covered by the order include widely used targeted therapies and immunotherapies. Medications like bevacizumab, pembrolizumab, palbociclib, and cetuximab are all subject to the new pricing structure, regardless of dosage strength, route of administration, or combination form.[3]

Generic cancer drugs will experience some of the steepest reductions under the revised framework. For instance, a pack of 21 palbociclib 100-milligram capsules will fall from 24,505 rupees to just 2,068 rupees, while a vial of the chemotherapy drug thiotepa drops from over 80,000 rupees to about 7,150 rupees.[2][6]

The list also covers essential supportive care medications used during chemotherapy. Drugs like pegfilgrastim, which prevents severe neutropenia in cancer patients, will see their margins strictly controlled, lowering the overall cost of managing treatment side effects.[2]

The revised prices take effect on November 9, 2026, and manufacturers have been directed to maintain current production levels. State drug controllers and hospitals are tasked with monitoring compliance to ensure the supply of these critical medicines remains uninterrupted during the transition.

Addressing the cost of survival

India registers more than 1.5 million new cancer cases annually, and the financial toxicity of treatment is a well-documented crisis. Medical expenses push an estimated 55 million Indian citizens into poverty each year, with oncology care being a primary driver of distress financing.[1][6]

A recent longitudinal survey of breast cancer patients in Mumbai found that over 84 percent experienced catastrophic health expenditure. Nearly 80 percent of those patients had to rely on multiple financing sources, including selling assets or taking out loans, to afford their care.[3]

Even among patients who had some form of health reimbursement, the incidence of catastrophic expenditure was only reduced by 14 percent. The sheer cost of oncology drugs easily outpaces standard insurance coverage, leaving families to bridge the gap out of pocket.[3]

"The decision is a welcome step if the outcome is that more patients can access the drugs they need," said Ravi Kannan, director of the Cachar Cancer Hospital and Research Centre in Assam. For many families, the price reductions mean the difference between completing a treatment regimen and abandoning it.[1]

The 137-drug list expands upon a 2019 pilot program in which the pricing authority capped margins on 42 anti-cancer medications. That earlier intervention successfully reduced the retail prices of 526 brands by up to 90 percent, demonstrating that margin rationalization can yield immediate benefits for patients.[3][6]

However, patient advocacy groups note that the 2019 price cuts did not create a permanent check on the broader market. The scale of the current reductions highlights how much room remained for prices to climb in the unregulated segments of the pharmaceutical supply chain over the last seven years.[6]

The limits of the current intervention

While generic and biosimilar medications will see dramatic price drops, the maximum retail prices of several high-cost, single-source patented drugs remain unchanged. Top-selling treatments like pembrolizumab and nivolumab are not expected to become cheaper under the current calculation mechanism.[2]

Because the margin cap is calculated based on the price to the stockist, manufacturers of expensive patented drugs who already sell at high wholesale prices are largely unaffected. A 100-milligram infusion of nivolumab, for example, will remain priced at over 109,000 rupees.[2]

Health policy experts point out that patient assistance programs offered at private hospitals can sometimes lower the effective purchase price of these patented drugs. Nevertheless, the upfront sticker price remains a formidable barrier for the vast majority of uninsured patients seeking advanced immunotherapies.[2]

There is also concern that hospitals might attempt to offset the lost pharmacy revenue by increasing other administrative charges. If the cost of administering the drug or general hospital fees rise, the net savings for the patient could be diluted, undermining the government's intent.[5]

The Supreme Court has recognized this loophole and is currently weighing whether to extend price regulation beyond cancer medicines. During an October 27 hearing, the bench asked the government to explain why trade margin caps should not apply to all non-scheduled drugs across the country.[1][3]

AI

A blueprint for broader reform

The pricing authority's action represents a significant shift in how India balances pharmaceutical commerce with public health imperatives. By targeting the distribution markup rather than the manufacturer's launch price, the government is attempting to protect patients without stifling drug development.[3][5]

Currently, only about 20 percent of India's 125 billion rupee cancer drug market is under strict price control. The remaining 80 percent consists of non-scheduled drugs, which have historically been free from price ceilings, allowing margins to balloon unchecked.[3]

The government has assured the court that the new framework covers all drugs approved for the treatment of cancer, except those that are already inexpensive. This comprehensive approach prevents distributors from simply shifting their focus to unregulated, high-margin alternatives.[5]

The expert committee that selected the 137 drugs has indicated that the list will be updated periodically based on market developments. This creates a flexible regulatory framework that can respond to the introduction of new therapies and shifting public health needs.

State drug controllers have been granted stronger enforcement powers to ensure the new prices are honored at the pharmacy counter. Hospitals will be required to separately disclose medicine prices, discounts, and administrative charges to prevent hidden cost-shifting.[5]

For the patients who will begin paying the revised prices next week, the policy is a tangible victory. It translates clinical breakthroughs into accessible treatments, ensuring that life-saving science is not locked behind insurmountable financial barriers.[4]

As the Supreme Court continues to deliberate on the broader pharmaceutical market, the cancer drug margin cap serves as a critical test case. If successful, it could pave the way for a more equitable healthcare system where the cost of a medicine reflects its clinical value.[5]